SCHEMBL7004166

SCHEMBL7004166

CC(C)(C)OC(=O)N1c2c(cccc2C(=O)O)CCC1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.35
GAA P10253 1/20 0.33
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
PRMT5 O14744 2/20 0.33
WDR77 Q9BQA1 2/20 0.33
TOP2A P11388 1/20 0.32
DDB1 Q16531 1/20 0.32
CRBN Q96SW2 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
UCHL1 P09936 1/20 0.32
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KDM4E B2RXH2 1/20 0.31
PKM P14618 1/20 0.31
NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7001472 0.91 PARP1 (0.38) HSD11B1PARP1
SCHEMBL7007832 0.83 MTNR1A (0.38) SMN1; SMN2MEN1KMT2A
SCHEMBL7001564 0.82 HTR1A (0.35) PARP1
SCHEMBL958204 0.76 CHRM2 (0.35) MEN1KMT2ATOP2ADDB1CRBN
SCHEMBL211419 0.76 CHRM2 (0.35) MEN1KMT2ATOP2ADDB1CRBN
SCHEMBL625416 0.76 CHRM2 (0.35) MEN1KMT2ATOP2ADDB1CRBN
SCHEMBL7005115 0.75 ACE (0.41) MEN1KMT2A
SCHEMBL30681436 0.71 SCN9A (0.40) THRBSMN1; SMN2GPR119
SCHEMBL30681463 0.71 SCN9A (0.40) THRBSMN1; SMN2GPR119
SCHEMBL30681403 0.70 NOTUM (0.37) GAATHRBSMN1; SMN2DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 HSD11B1 1000/4885GAA 2567/4885THRB 1786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.